バイオセンサー市場：タイプ、用途、技術、エンドユーザー、地域別、2026-2032年

バイオセンサー市場の評価、2026-2032年

ナノテクノロジーとマイクロエレクトロニクスの革新が、感度と特異性を高め、バイオセンサーの採用を促進しています。慢性疾患の増加により、バイオセンサーが提供する継続的なモニタリングソリューションへの需要が高まり、市場規模は2024年に333億米ドルを突破し、2032年には約605億米ドルの評価額に達します。

これに加えて、ヘルスケアインフラへの投資と研究開発の増加が、高度なバイオセンシング技術の開発を後押しし、バイオセンサーの採用に拍車をかけています。ポイントオブケア診断に対する需要の高まりが、ポータブルで使いやすいバイオセンサの採用を後押ししており、2026年から2032年にかけてのCAGRは8.55%です。

バイオセンサー市場定義/概要

バイオセンサーは、生体反応を電気信号に変換し、様々な物質の検出と定量を可能にする分析装置です。バイオセンサーは通常、酵素、抗体、微生物などの生物学的検出素子と、生化学的相互作用を測定可能な信号に変換する変換器とで構成されます。この技術は、迅速、高感度、特異的な分析を提供し、様々な分野で貴重なものとなっています。

バイオセンサーの用途は広大で多様です。ヘルスケアでは、糖尿病患者のグルコースレベルのモニタリング、病原菌の検出、ポイントオブケア診断などに使用されています。環境モニタリングも重要な分野で、バイオセンサーは水や土壌中の汚染物質や病原体を検出し、公共の安全と環境保護の確保に役立っています。さらに、バイオセンサーは食品安全にも利用されており、汚染物質の迅速な検査や食品の品質確保を可能にしています。

労働力管理はどのようにバイオセンサーの採用を増やすのか？

慢性疾患の有病率の上昇と、迅速で正確な診断ソリューションに対する需要の高まりが、バイオセンサー市場を大きく前進させています。世界保健機関（WHO）の2023年世界保健報告（Global Health Report）によると、糖尿病は世界で約5億3,700万人の成人が罹患しており、連続グルコースモニタリング用バイオセンサーの必要性を高めています。人工知能とIoT機能の統合は、リアルタイムのデータ分析と遠隔患者モニタリングを通じて、疾患のモニタリングと管理に革命をもたらしました。この動向は、アボット・ラボラトリーズが2024年3月に糖尿病管理のための精度の向上とスマートフォン接続を特徴とする新しいFreeStyle Libre 4システムを発売したことで勢いを増しました。

COVID-19の大流行は、ヘルスケア環境全体におけるポイントオブケア検査とバイオセンサー技術の採用を加速させました。米国疾病管理予防センターは、バイオセンサー技術を活用した迅速診断検査により、2023年には従来の検査室での検査方法と比較して平均診断時間が65%短縮されたと報告しています。疾病の早期発見と予防ヘルスケアの重視は、バイオセンサーの研究開発に多額の投資を促しています。2024年2月、ロシュ・ダイアグノスティックスは心臓バイオマーカー検出用の最新バイオセンサープラットフォームを発表しました。

環境モニタリングと食品安全への懸念は、バイオセンサー技術採用の重要な推進力として浮上しています。欧州食品安全局の2023年報告書では、バイオセンサーに基づく食品検査法は従来の検査アプローチよりも40％早く汚染物質を検出することが示されています。小型化された携帯型バイオセンサーの開発により、農業から環境保護まで、さまざまな産業でその用途が広がっています。この市場の進化は、2024年1月にサーモ・フィッシャー・サイエンティフィック社がバイオセンサー技術の主要企業を買収し、環境汚染物質検出用の新しいマルチプレックス・バイオセンサー・プラットフォームを発表したことで浮き彫りになりました。

標準化された試験と品質管理対策の欠如はバイオセンサー市場の成長を抑制するか？

データ管理と相互運用性の問題も課題となっています。バイオセンサーがますます大量のデータを生成するようになるにつれ、効果的なデータ統合と解析の確保が極めて重要になります。多くのヘルスケアプロバイダーや検査室は、こうしたデータの管理に苦労しており、特にバイオセンサーを既存のシステムに統合する際には、臨床現場での採用の妨げになりかねないです。

もう一つの大きな制約は、規制当局の承認プロセスの複雑さです。バイオセンサー、特に医療用途で使用されるものは、安全性と有効性の基準を満たすために厳格な試験と検証を受けなければならないです。この長くてコストのかかる承認プロセスは、新しいバイオセンサー製品の市場導入を遅らせ、投資や技術革新を阻害します。

さらに、バイオセンサー業界全体では、標準化された試験や品質管理手段が不足しています。標準化されたプロトコールがなければ、メーカーが製品の信頼性と再現性を確保することは難しいです。このような矛盾は、バイオセンサーの性能に関してユーザーやヘルスケア専門家の懐疑心を招き、市場の受容を遅らせることになります。

目次

第1章 世界のバイオセンサー市場の導入

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界のバイオセンサー市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 世界のバイオセンサー市場、タイプ別

• 概要
• ウェアラブル
• 埋め込み型
• 非ウェアラブル

第6章 世界のバイオセンサー市場：エンドユーザー別

• 概要
• 病院・クリニック
• 診断研究所
• 飲食品
• 環境モニタリング機関
• 製薬・バイオテクノロジー企業
• 研究機関・アカデミア

第7章 世界のバイオセンサー市場、技術別

• 概要
• 電気化学
• 光学式
• 圧電
• 熱
• ナノメカニカル

第8章 世界のバイオセンサー市場：用途別

• 概要
• 医療診断
• 食品分析
• 環境モニタリング
• 産業プロセス制御
• 農業検査、バイオディフェンス

第9章 世界のバイオセンサー市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第10章 世界のバイオセンサー市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第11章 企業プロファイル

• Abbott Laboratories
• Siemens Healthineers
• Roche Diagnostics
• Medtronic
• Honeywell International, Inc.
• Danaher Corporation
• LifeSensors Inc.
• Johnson & Johnson
• Thermo Fisher Scientific, Inc.

第12章 主な発展

• 製品の上市／開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第13章 付録

• 関連調査

Biosensors Market Valuation - 2026-203

Innovations in nanotechnology and microelectronics enhance the sensitivity and specificity is propelling the adoption of biosensors. Increasing prevalence of chronic diseases drives demand for continuous monitoring solutions provided by biosensors is driving the market size surpass USD 33.3 Billion valued in 2024 to reach a valuation of around USD 60.5 Billion by 2032.

In addition to this, increased investment in healthcare infrastructure and research fuels the development of advanced biosensing technologies is spurring up the adoption of biosensors. Rising demand for point-of-care diagnostics drives the adoption of portable and user-friendly biosensors is enabling the market to grow at a CAGR of 8.55% from 2026 to 2032.

Biosensors Market: Definition/Overview

Biosensors are analytical devices that convert a biological response into an electrical signal, allowing for the detection and quantification of various substances. They typically consist of a biological sensing element, such as enzymes, antibodies, or microorganisms, integrated with a transducer that converts the biochemical interaction into a measurable signal. This technology offers rapid, sensitive, and specific analysis, making it invaluable in various fields.

The applications of biosensors are vast and diverse. In healthcare, they are used for monitoring glucose levels in diabetic patients, detecting pathogens, and conducting point-of-care diagnostics. Environmental monitoring is another critical area, where biosensors can detect pollutants and pathogens in water and soil, helping to ensure public safety and environmental protection. Additionally, biosensors find uses in food safety, allowing for the rapid testing of contaminants and ensuring the quality of food products.

How will Workforce Management Increase Adoption of Biosensors?

The rising prevalence of chronic diseases and the growing demand for rapid, accurate diagnostic solutions have significantly propelled the biosensors market forward. According to the World Health Organization's 2023 Global Health Report, diabetes affects approximately 537 million adults worldwide, driving the need for continuous glucose monitoring biosensors. The integration of artificial intelligence and IoT capabilities has revolutionized disease monitoring and management through real-time data analysis and remote patient monitoring. This trend gained momentum when Abbott Laboratories launched their new FreeStyle Libre 4 system in March 2024, featuring enhanced accuracy and smartphone connectivity for diabetes management.

The COVID-19 pandemic has accelerated the adoption of point-of-care testing and biosensor technology across healthcare settings. The U.S. Centers for Disease Control and Prevention reported that rapid diagnostic tests utilizing biosensor technology reduced average diagnosis time by 65% in 2023 compared to traditional laboratory testing methods. The emphasis on early disease detection and preventive healthcare has driven substantial investments in biosensor research and development. In February 2024, Roche Diagnostics introduced their latest biosensor platform for cardiac biomarker detection, offering results in under 8 minutes with improved sensitivity.

Environmental monitoring and food safety concerns have emerged as crucial drivers for biosensor technology adoption. The European Food Safety Authority's 2023 report indicated that biosensor-based food testing methods detected contaminants 40% faster than conventional testing approaches. The development of miniaturized, portable biosensors has expanded their applications across various industries, from agriculture to environmental protection. This market evolution was highlighted when Thermo Fisher Scientific announced in January 2024 its acquisition of a leading biosensor technology company and the launch of their new multiplex biosensor platform for environmental pollutant detection.

Will Lack of Standardized Testing and Quality Control Measures Restraining Biosensors Market Growth?

Data management and interoperability issues also present challenges. As biosensors increasingly generate large volumes of data, ensuring effective data integration and analysis becomes crucial. Many healthcare providers and laboratories struggle with managing this data, particularly when integrating biosensors with existing systems, which can hinder their adoption in clinical settings.

Another significant restraint is the complexity of regulatory approval processes. Biosensors, especially those used in medical applications, must undergo rigorous testing and validation to meet safety and efficacy standards. This lengthy and often costly approval process can slow down the introduction of new biosensor products into the market, deterring investment and innovation.

Additionally, there is a lack of standardized testing and quality control measures across the biosensor industry. Without standardized protocols, it can be difficult for manufacturers to ensure the reliability and reproducibility of their products. This inconsistency can lead to skepticism among users and healthcare professionals regarding the performance of biosensors, slowing market acceptance.

Category-Wise Acumens

Will Rise in Adoption of Non-Wearable Biosensor Drive Biosensors Market Growth?

The non-wearable biosensor segment dominates the market, primarily driven by its widespread application in clinical diagnostics and laboratory settings. According to the National Institutes of Health's 2023 Medical Device Report, non-wearable biosensors accounted for 65% of all biosensor implementations in healthcare facilities, demonstrating their crucial role in diagnostic procedures. These devices offer superior sensitivity and specificity compared to their wearable counterparts, making them indispensable for accurate disease detection and monitoring. The segment's growth was further emphasized when Siemens Healthineers launched their advanced non-wearable biosensor platform in March 2024, featuring multiplexed detection capabilities for various biomarkers.

Point-of-care testing applications have significantly boosted the adoption of non-wearable biosensors in emergency departments and primary care settings. The U.S. Food and Drug Administration reported that non-wearable biosensor-based diagnostic tests reduced patient waiting times by 75% in 2023 compared to traditional laboratory methods. These devices enable rapid decision-making and immediate treatment initiation, particularly crucial in critical care scenarios. This trend was highlighted when Medtronic introduced its new non-wearable biosensor system in February 2024, designed for rapid cardiac biomarker detection with enhanced accuracy and reduced analysis time.

Will Rise in Adoption of Electrochemical Biosensors fuel Growth of Biosensors Market?

Electrochemical biosensors have established dominance in the market due to their exceptional sensitivity, cost-effectiveness, and rapid response capabilities in detecting biological analytes. The National Institute of Standards and Technology reported in 2023 that electrochemical biosensors demonstrated a 95% accuracy rate in glucose monitoring applications, significantly higher than other biosensor technologies. Their ability to provide quantitative results with minimal sample preparation has made them indispensable in clinical diagnostics and point-of-care testing. This technological advancement was highlighted when Dexcom introduced its next-generation electrochemical continuous glucose monitoring system in March 2024, featuring enhanced accuracy and extended sensor life.

The versatility of electrochemical biosensors in detecting various biomarkers has driven their widespread adoption in medical diagnostics and disease monitoring. According to the U.S. Food and Drug Administration's 2023 Medical Device Report, electrochemical biosensors accounted for 70% of all approved biosensor-based diagnostic devices. These sensors excel in providing real-time, label-free detection of biomolecules with high specificity. In February 2024, Roche Diagnostics launched their innovative electrochemical biosensor platform for cardiac biomarker detection, incorporating advanced electrode materials and improved signal processing capabilities.

Country/Region Wise Acumens

Will Advanced Healthcare Infrastructure in North America Bolster Expansion of Biosensors Market?

North America maintains its leadership position in the biosensors market, driven by advanced healthcare infrastructure and substantial investments in medical technology research and development. The U.S. Centers for Disease Control and Prevention reported in 2023 that biosensor adoption in American healthcare facilities increased by 45% compared to the previous year, highlighting the region's rapid technological integration. The presence of major market players and favorable regulatory frameworks has accelerated innovation in biosensor technology. This dominance was further solidified when Dexcom announced in March 2024 a USD 500 Million investment in expanding its biosensor manufacturing facilities across the United States, focusing on next-generation continuous glucose monitoring systems.

The region's robust pharmaceutical and biotechnology sectors have significantly contributed to biosensor market growth. According to the National Institutes of Health's 2023 Biomedical Research Report, North American institutions accounted for 55% of global biosensor-related patents and research publications. The increasing prevalence of chronic diseases and the growing demand for point-of-care diagnostics continue to drive market expansion. In February 2024, Abbott Laboratories secured FDA approval for their latest biosensor platform, featuring enhanced sensitivity for multiple biomarker detection and improved connectivity options for remote patient monitoring.

Will Rising Technological Advancements and Research Collaborations Enhance Adoption of Biosensors in Asia Pacific?

The Asia Pacific biosensors market is experiencing rapid growth, driven by increasing healthcare expenditure, rising chronic disease prevalence, and growing awareness of point-of-care diagnostics. Countries like China, Japan, and India are at the forefront of this expansion, with their large populations and improving healthcare infrastructure. According to a report by the World Health Organization, the Asia Pacific region accounted for 37% of the global medical devices market in 2020, indicating a strong foundation for biosensor adoption.

Technological advancements and research collaborations are further propelling the market forward. Universities and research institutions across the region are partnering with industry leaders to develop innovative biosensor technologies. For instance, in March 2024, the National University of Singapore announced a breakthrough in developing a highly sensitive graphene-based biosensor for rapid detection of infectious diseases. This innovation has the potential to revolutionize disease diagnosis and management in the region.

Competitive Landscape

The biosensors market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the biosensors market include:

• Abbott Laboratories
• Siemens Healthineers
• Roche Diagnostics
• Medtronic
• Honeywell International, Inc.
• Danaher Corporation
• Johnson & Johnson
• Thermo Fisher Scientific, Inc.
• GlaxoSmithKline plc
• Bayer AG
• GE Healthcare
• Sensirion AG
• Molecular Devices (A part of Danaher)
• Bio-Rad Laboratories, Inc.
• Schott AG
• Analytik Jena AG
• Eppendorf AG
• Novartis AG
• Acon Laboratories, Inc.
• Zymergen, Inc.
• Biosensors Market Latest Developments
• In October 2023, BioTech Innovations announced a partnership with HealthSense Technologies to develop advanced biosensors for real-time health monitoring, focusing on chronic disease management.
• In September 2023, researchers at Stanford University unveiled a groundbreaking biosensor capable of detecting multiple biomarkers from a single drop of blood, aiming for faster diagnostic capabilities in clinical settings.

Biosensors Market, By Category

• Type:
• Wearable
• Implantable
• Non-Wearable
• Application:
• Medical Diagnostics
• Food Analysis
• Environmental Monitoring
• Industrial Process Control
• Agricultural Testing, Biodefense
• Technology:
• Electrochemical
• Optical
• Piezoelectric
• Thermal
• Nanomechanical
• End-Users:
• Hospitals & Clinics
• Diagnostic Laboratories
• Food & Beverage
• Environmental Monitoring Agencies
• Pharmaceutical & Biotechnology Companies
• Research Institutes & Academia
• Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL BIOSENSORS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL BIOSENSORS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL BIOSENSORS MARKET, BY TYPE

• 5.1 Overview
• 5.2 Wearable
• 5.3 Implantable
• 5.4 Non-Wearable

6 GLOBAL BIOSENSORS MARKET, BY END-USERS

• 6.1 Overview
• 6.2 Hospitals & Clinics
• 6.3 Diagnostic Laboratories
• 6.4 Food & Beverage
• 6.5 Environmental Monitoring Agencies
• 6.6 Pharmaceutical & Biotechnology Companies
• 6.7 Research Institutes & Academia

7 GLOBAL BIOSENSORS MARKET, BY TECHNOLOGY

• 7.1 Overview
• 7.2 Electrochemical
• 7.3 Optical
• 7.4 Piezoelectric
• 7.4 Thermal
• 7.5 Nanomechanical

8 GLOBAL BIOSENSORS MARKET, BY APPLICATION

• 8.1 Overview
• 8.2 Medical Diagnostics
• 8.3 Food Analysis
• 8.4 Environmental Monitoring
• 8.5 Industrial Process Control
• 8.6 Agricultural Testing, Biodefense

9 GLOBAL BIOSENSORS MARKET, BY GEOGRAPHY

• 9.1 Overview
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 U.K.
  • 9.3.3 France
  • 9.3.4 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Rest of Asia Pacific
• 9.5 Rest of the World
  • 9.5.1 Latin America
  • 9.5.2 Middle East and Africa

10 GLOBAL BIOSENSORS MARKET COMPETITIVE LANDSCAPE

• 10.1 Overview
• 10.2 Company Market Ranking
• 10.3 Key Development Strategies

11 COMPANY PROFILES

• 11.1 Abbott Laboratories
  • 11.1.1 Overview
  • 11.1.2 Financial Performance
  • 11.1.3 Product Outlook
  • 11.1.4 Key Developments
• 11.2 Siemens Healthineers
  • 11.2.1 Overview
  • 11.2.2 Financial Performance
  • 11.2.3 Product Outlook
  • 11.2.4 Key Developments
• 11.3 Roche Diagnostics
  • 11.3.1 Overview
  • 11.3.2 Financial Performance
  • 11.3.3 Product Outlook
  • 11.3.4 Key Developments
• 11.4 Medtronic
  • 11.4.1 Overview
  • 11.4.2 Financial Performance
  • 11.4.3 Product Outlook
  • 11.4.4 Key Developments
• 11.5 Honeywell International, Inc.
  • 11.5.1 Overview
  • 11.5.2 Financial Performance
  • 11.5.3 Product Outlook
  • 11.5.4 Key Developments
• 11.6 Danaher Corporation
  • 11.6.1 Overview
  • 11.6.2 Financial Performance
  • 11.6.3 Product Outlook
  • 11.6.4 Key Developments
• 11.7 LifeSensors Inc.
  • 11.7.1 Overview
  • 11.7.2 Financial Performance
  • 11.7.3 Product Outlook
  • 11.7.4 Key Developments
• 11.8 Johnson & Johnson
  • 11.8.1 Overview
  • 11.8.2 Financial Performance
  • 11.8.3 Product Outlook
  • 11.8.4 Key Developments
• 11.9 Thermo Fisher Scientific, Inc.
  • 11.9.1 Overview
  • 11.9.2 Financial Performance
  • 11.9.3 Product Outlook
  • 11.9.4 Key Developments

12 KEY DEVELOPMENTS

• 12.1 Product Launches/Developments
• 12.2 Mergers and Acquisitions
• 12.3 Business Expansions
• 12.4 Partnerships and Collaborations

13 Appendix

• 13.1 Related Research